Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1489-1496
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1489
Figure 2 Comparisons of the infliximab trough levels and antibody to infliximab levels between patients with quiescent or active disease.
The median infliximab trough levels (IFX-TLs) were 1.423 μg/mL (IQR 0.877-2.483) and 0.163 μg/mL (IQR 0.002-0.636), respectively (P < 0.001) (A) and the median antibodies to infliximab (ATIs) levels were 8.064 AU/mL (IQR 6.929-9.908) and 11.209 AU/mL (IQR 8.008-118.835), respectively (P < 0.001) (B) in patients with quiescent and active disease.
- Citation: Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496
- URL: https://www.wjgnet.com/1007-9327/full/v23/i8/1489.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i8.1489